Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Para-aminosalicylic acid (PAS)→

Para-aminosalicylic acid (PAS) Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
65-49-6
PubChem CID
4649
Molecular formula
C7H7NO3
Molecular weight
153.14 g/mol

Identification source: PubChem record (CID 4649). Para-aminosalicylic acid is also named 4-aminosalicylic acid in the linked PubChem record.

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Second-line antitubercular; para-aminobenzoic acid (PABA) analogue and antifolate

Mechanism of action

A prodrug incorporated by mycobacterial folate-pathway enzymes to form a hydroxylated dihydrofolate antimetabolite that inhibits dihydrofolate reductase. It also interferes with folate and mycobactin-related pathways and has bacteriostatic activity against Mycobacterium tuberculosis.

General use cases

  • Companion drug in selected multidrug regimens for drug-resistant tuberculosis when recommended by current WHO or national treatment guidance.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Para-aminosalicylic acid (PAS) Environmental Risk Assessment (ERA) (the Para-aminosalicylic acid (PAS) ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.